Skip to main content

 

Principal Investigator: 

 

Professor David Grieve

 

Name of the Study:

GLP-1 and cardiac inflammation in diabetes – Investigating the effects of glucagon-like peptide-1 (GLP-1) on circulating inflammatory cell profile and cardiac function in patients with type 2 diabetes.

        

Why is this Study important?

The incidence of diabetes is rapidly increasing and is particularly linked with increased risk of heart failure. This is thought to be caused by specific changes which occur in the hearts of diabetic patients due to elevated glucose levels. This study will highlight GLP-1 as an improved therapy for heart failure in diabetes which would enhance survival and quality of life.

 

What is the Research question/aim?

Previous work has indicated that a naturally occurring protein, called GLP-1, used to reduce blood glucose in diabetes, also exerts beneficial effects on the heart, It appears to do this by altering two important processes in the heart known as inflammation and extracellular matrix remodelling which cause it to become stiffer and less able to pump blood. The study will investigate mechanisms which GLP-1 affects these processes in diabetic patients, specifically focusing on circulating inflammatory cells which are important in heart failure.

 

What the Study involves: 

One visit to the NICRF which will involve consent and blood sampling followed by a cardiac ultrasound sound scan (ECHO) in the Cardiology Department. Visits will take approximately 2 hours in total and the results of the ECHO will be discussed.

 

PPI Involvement: 

We frequently host site visits to our research centre from charitable organisations, including Diabetes UK and the British Heart Foundation, which provide us with regular opportunities to discuss our research with people affected by diabetes and to gain their feedback and input into our work. Outcomes from this project will be communicated to the wider public through these outreach events, and our other public engagement activities, such as the NI Science Festival, Pint of Science Festival, and Belfast Cityheart patient group meetings.

 

Who can take part in the Study?

Adults aged between 40-65 years who have a good understanding of English, are compliant with treatment, do not have underlying cardiac disease, are within specified HbA1c and BMI parameters, and are receiving standard diabetic medication but not insulin. Study eligibility will be assessed by the direct clinical care team at RVH.

 


 

Contact Information:

Professor David Grieve

Principal Investigator

Wellcome-Wolfson Institute for Experimental Medicine

Queen’s University Belfast

97 Lisburn Road

d.grieve@qub.ac.uk

 

Dr Chris Watson

Co-Investigator

Wellcome-Wolfson Institute for Experimental Medicine

Queen’s University Belfast

97 Lisburn Road

chris.watson@qub.ac.uk

 

Dr Adrien Kissenpfennig

Co-Investigator

Wellcome-Wolfson Institute for Experimental Medicine

Queen’s University Belfast

97 Lisburn Road

a.kissenpfennig@qub.ac.uk

 

Dr Hamish Courtney

Clinical Collaborator

Regional Centre for Diabetes and Endocrinology

Royal Victoria Hospital

Grosvenor Road

 hamish.courtney@belfasttrust.hscni.net

 

Dominica Martin

Research Nurse

NICRF

U Floor

Belfast City Hospital

martin@belfasttrust.hscni.net

Location:

NI Clinical Research Facility,

U Floor, Belfast City Hospital,

Lisburn Road, Belfast, BT9 7AB

 

Tel:+44 (0)28 9504 0342

Email:NICRF@qub.ac.uk

 
Connect to the NICRF